I agree that their limited disclosure is frustrating. For one reason or another, they are a public company, still operating as if it was still a private company. It would be a good fit within their current infrastructure.
According United Therapeutic's 10-k filing:
However, the growth rate YOY for 2024 Q1 was over 20%, hopefully this a trend that keeps going creating a larger market by the time ANIP launches. So it looks like a good revenue generator for 2028 if not sooner.
They also have approval for a generic of AbbVie's Namzaric (21mg ) and tentative approval for the 28mg. Not sure when they can launch, as ANIP acquired it from Amerigen who was in patent infringement litigation with Forrest Labs ( AbbVie) but in the approval letter from the FDA it listed the following.
Agency’s publication titled Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”): U.S. Patent Number Expiration Date 8,039,009 (the '009 patent) September 24, 2029* 8,058,291 (the '291 patent) December 5, 2029 8,168,209 (the '209 patent) May 22, 2026* 8,173,708 (the '708 patent) May 22, 2026* 8,283,379 (the '379 patent) May 22, 2026* 8,293,794 (the '794 patent) November 22, 2025 8,329,752 (the '752 patent) May 22, 2026* 8,338,485 (the '485 patent) November 22, 2025 8,338,486 (the '486 patent) November 22, 2025 8,362,085 (the '085 patent) May 22, 2026* 8,580,858 (the '858 patent) November 22, 2025 8,598,233 (the '233 patent) May 22, 2026* *with pediatric exclusivity added .
The patent infringement case was dismissed. So it unknown if a settlement was reached and if a date ANIP could launch was part of a deal.